Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma

INTRODUCTION: Current treatments for patients with previously treated advanced hepatocellular carcinoma (HCC) provide modest survival benefits. We evaluated the safety and antitumor activity of serplulimab, an anti-PD-1 antibody, plus the bevacizumab biosimilar HLX04 in this patient population. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Zhenggang, Shao, Guoliang, Shen, Jie, Zhang, Li, Zhu, Xu, Fang, Weijia, Sun, Guoping, Bai, Yuxian, Wu, Jianbing, Liu, Lianxin, Yuan, Yuan, Zhang, Jingdong, Li, Zhen, Zhang, Ling, Yin, Tao, Wu, Jincai, Hou, Xiaoli, Wang, Qingyu, Zhu, Jun, Fan, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267516/
https://www.ncbi.nlm.nih.gov/pubmed/37325495
http://dx.doi.org/10.1159/000526638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267516/
https://www.ncbi.nlm.nih.gov/pubmed/37325495
http://dx.doi.org/10.1159/000526638

Ejemplares similares